REV1 and cancer: Finally, an analysis of available genome-wide drop-out CRISPR screens across cell lines with and without APOBEC3 signature mutations failed to show an increased dependence on REV1 in cancer cell lines containing SBS2/13 mutations (Methods and Extended Data Fig. 9j).